

# Adipose-derived stem cells express higher levels of type VII collagen under specific culture conditions

メタデータ	言語: English 出版者: 公開日: 2018-03-20 キーワード (Ja): キーワード (En): 作成者: 前田, 佑一郎 メールアドレス: 所属:
URL	<a href="https://jair.repo.nii.ac.jp/records/2002098">https://jair.repo.nii.ac.jp/records/2002098</a>

*Archives of Dermatological Research*

*Concise Communication*

**Adipose-derived stem cells express higher levels of type VII collagen under specific culture conditions**

**Yuichiro Maeda<sup>1</sup>, Toshio Hasegawa<sup>1\*</sup>, Akino Wada<sup>1</sup>, Tatsuo Fukai<sup>1</sup>, Hideo Iida<sup>1</sup>,  
Atsushi Sakamoto<sup>1</sup>, and Shigaku Ikeda<sup>1,2</sup>**

<sup>1</sup> Department of Dermatology and Allergology, Juntendo University Graduate School of Medicine, Tokyo Japan

<sup>2</sup> Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Tokyo Japan

**\*Corresponding author:** Toshio Hasegawa, M.D., Ph.D.

2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, JAPAN

TEL: +81-3-5802-1226 FAX: +81-3-3813-9443

E-mail: t-hase@juntendo.ac.jp

1978 words; 11 references; no tables; 3 figures

**Abbreviations:** Col7, type VII collagen; ADSC, adipose-derived stem cell; K14, cytokeratin 14; NHEK, normal human epidermal keratinocyte; HRP, horseradish peroxidase; NHDF, normal human dermal fibroblast; DMEM, Dulbecco's modified Eagle's Medium; ATRA, all-trans retinoic acid; BMP4, bone-morphogenetic protein-4; KSFM, keratinocyte serum-free medium; K5, cytokeratin 5; K10, cytokeratin 10; DAPI, 4,6-diamidino-2-phenylindole; RDEB, recessive dystrophic epidermolysis bullosa

## **Abstract**

Type VII collagen (Col7) is a major component of the anchoring fibrils at the dermoepidermal junction. Adipose-derived stem cells (ADSCs) are a cell population highly useful in regenerative medicine because of their ease of isolation and their potential for multilineage differentiation. Based on the observations that K14 was expressed in undifferentiated ADSCs and the expression was downregulated after differentiation into adipocytes, we speculated that ADSCs are keratinocyte stem/progenitor cells. ADSCs were co-cultured with fibroblasts on type IV collagen in a medium containing all-trans retinoic acid and bone morphogenetic protein 4. At day 14 of culture in keratinocyte serum-free medium, the cells were harvested and subjected to immunofluorescence, flow cytometry, real-time PCR, and western blotting. Approximately 45% of ADSCs were immunostained positively for anti-human cytokeratin 10, and approximately 80% were stained positively for Col7. Flow cytometry, real-time PCR, and western blotting also confirmed that differentiated ADSCs expressed higher levels of Col7. These findings support the therapeutic potential of ADSCs, not only for wound healing, but also for the correction of Col7 deficiencies.

**Key words**

adipose-derived stem cell; keratinocyte; type VII collagen; cytokeratin

## **Introduction**

Type VII collagen (Col7), which is synthesized by both basal keratinocytes and dermal fibroblasts in human skin, is a major component of the anchoring fibrils at the dermoepidermal junction. Anchoring fibrils provide a structural attachment between the epidermal basement membrane and papillary dermis. Adipose-derived stem cells (ADSCs) are a cell population highly useful in regenerative medicine because of their ease of isolation and their potential for multilineage differentiation [11]. In this study, we investigated whether ADSCs express Col7 to determine the potential of these cells to provide epidermal cover and rescue basement membrane defects.

## **Materials and methods**

### **K14 detection in undifferentiated ADSCs by immunofluorescence and flow cytometry**

Undifferentiated ADSCs (Lonza Group AG, MA, CHE) were first immunostained for human cytokeratin 14 (K14) using rabbit polyclonal anti-cytokeratin 14 (Covance, NJ,

USA), with normal human epidermal keratinocytes (NHEKs; Kurabo, Osaka, Japan) used as a positive control.

Undifferentiated ADSCs were also incubated with FITC-conjugated anti-K14 antibody (Abcam, Cambridge, UK) and analyzed by flow cytometry.

### **K14 detection in adipocyte-differentiated ADSCs by real-time PCR**

ADSCs were differentiated into adipocytes as previously described [10]. K14 expression before and after the differentiation of ADSCs into adipocytes was evaluated by real-time PCR. Total RNA extracted from ADSCs was converted into cDNA using the ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan). TaqMan Master Mix (Applied Biosystems, CA, USA) was used to amplify cDNA for 45 cycles on a StepOnePlus System (Applied Biosystems). K14 expression (using primers Hs00265033\_m1; Applied Biosystems) was normalized to  $\beta$ -actin levels, and the comparative cycle threshold (Ct) method, using the formula  $2^{-\Delta\Delta Ct}$ , was used to calculate relative mRNA levels.

### **K14 detection in adipocyte-differentiated ADSCs by western blotting**

K14 expression before and after the differentiation of ADSCs into adipocytes was also evaluated by western blotting after ADSCs were harvested and lysed. Proteins were separated by gel electrophoresis and transferred to a nitrocellulose membrane, which was incubated with primary antibodies against K14 (Covance, NJ, USA).  $\beta$ -actin expression detected using a monoclonal antibody (BioLegend, CA, USA) was used as a loading control. The membrane was then washed, incubated with an anti-rabbit IgG horseradish peroxidase (HRP)-linked secondary antibody (Cell Signaling Technology, MA, USA), and developed with Super Signal West Dura Extended Duration Substrate (Thermo Fisher Scientific).

### **Differentiation of ADSCs into keratinocyte-like cells**

A co-culture system was used to differentiate ADSCs into keratinocyte-like cells [2].

Normal human dermal fibroblasts (NHDFs) ( $5 \times 10^4$  cells/ml) were seeded in the bottom chambers of 6-well plates and cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Thermo Fisher Scientific) containing 10% fetal bovine serum for 24 h, while ADSCs ( $1 \times 10^5$  cells/ml) were seeded on 0.4- $\mu$ m Millicell<sup>R</sup> hanging cell culture inserts



(Merck Millipore, Darmstadt, Germany) coated with type IV collagen (Nitta Gelatin, Osaka, Japan) and placed into the plates. All-trans retinoic acid (ATRA) (Sigma-Aldrich, MO, USA) was added at a concentration of 1  $\mu$ M to the upper chamber, and cells were cultured for three days. Bone morphogenetic protein 4 (BMP4) (R&D Systems, MN, USA) was then added at 25 ng/ml to the upper chamber. After four days of culture, the ATRA- and BMP4-containing media were replaced with keratinocyte serum-free medium (KSFM) (Thermo Fisher Scientific). At day seven of culture in KSFM, ADSCs were removed from the co-culture system and cultured on dish coated with type IV collagen for an additional 14 days in KSFM.

### **K10 detection in differentiated ADSCs by immunofluorescence and flow cytometry**

ADSCs were immunostained for human cytokeratin 10 (K10) using mouse monoclonal anti-K10 (Abcam). Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI). Samples were mounted in Mounting Medium with DAPI H-1200 (Vector Laboratories, CA, USA) to detect fluorescence, visualized under a BZ-X700 microscope (KEYENCE, Tokyo, Japan), and analyzed using Hybrid Cell Count software

(KEYENCE). Five independent samples were analyzed per time point. The average number of positively stained cells was divided by the average number of total cells and multiplied by 100 to obtain the percentage. Undifferentiated ADSCs and normal human epidermal keratinocytes (NHEKs) were used as negative and positive controls, respectively.

Undifferentiated ADSCs were also incubated with FITC-conjugated anti-K10 antibody (Abcam) and analyzed by flow cytometry.

#### **K10 detection in differentiated ADSCs by real-time PCR**

K10 expression was confirmed by real-time PCR using the same method used to quantify K14 (using primers Hs01043114; Applied Biosystems).

#### **Col7 detection in differentiated ADSCs by immunofluorescence and flow cytometry**

Col7 expression in ADSCs on day 14 after removal from the co-culture system was detected by immunofluorescence. Samples were mounted, visualized, and analyzed using the same method to quantify K10 with primary antibodies against Col7 (Abcam). Five

independent samples were analyzed per time point. The average number of positively stained cells was divided by the average number of total cells and multiplied by 100 to obtain the percentage. Undifferentiated ADSCs and normal human epidermal keratinocytes (NHEKs) were used as negative and positive controls, respectively. Undifferentiated ADSCs were also incubated with FITC-conjugated anti-Col7 antibody (Abcam) and analyzed by flow cytometry.

#### **Col7 detection in differentiated ADSCs by real-time PCR**

Col7 expression was confirmed by real-time PCR using the same method used to quantify K14 and K10 (using primers Hs00164310\_m1; Applied Biosystems).

#### **Col7 detection in differentiated ADSCs by western blotting (Wet transfer)**

Col7 expression in ADSCs was also assessed by western blotting after cells were harvested and lysed with M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientific) in the presence of Protease Inhibitor Cocktail (Sigma-Aldrich). Proteins were separated by 10% Tris-glycine SDS-PAGE (Bio-Rad, CA, USA) under denaturing

conditions and transferred to a nitrocellulose membrane, which was incubated with primary antibodies against Col7 (1:0.8  $\mu\text{g}/\text{mL}$ ; Abcam). The blot for  $\beta$ -actin was confirmed using a monoclonal antibody (1:2000; BioLegend) as a loading control. The membrane was then washed, incubated with anti-rabbit IgG HRP-linked antibody (1:2500; Cell Signaling Technology), and developed with Super Signal West Dura Extended Duration Substrate (Thermo Fisher Scientific). Undifferentiated ADSCs, NHEKs, and ADSCs co-cultured with NHDFs without ATRA and BMP4 were also used as controls. Multi Gauge Software (Fujifilm, Tokyo, Japan) was used for visualization and quantification of bands.

### **Statistical analysis**

Data were analyzed by analysis of variance and are presented as the mean  $\pm$  standard error (SE) from at least three independent experiments. Statistical significance was analyzed using Student's t-test for each paired experiment.

### **Results**

### **K14 expression in ADSCs decreased after differentiation into adipocytes**

The undifferentiated ADSCs expressed K14 as determined by immunofluorescence microscopy (Fig. 1A) and flow cytometry (Fig. 1B).

Adipocyte-differentiated ADSCs expressed lower levels of K14 than undifferentiated ADSCs as determined by both real-time PCR (Fig. 1C) and western blotting (Fig. 1D).

These observations were consistent across three independent experiments performed using ADSCs from three different lots. Based on the present observations that K14 was expressed in undifferentiated ADSCs and the expression was downregulated after differentiation into adipocytes, we speculated that ADSCs are keratinocyte stem/progenitor cells.

### **45% of differentiated ADSCs expressed K10**

The differentiated ADSCs displayed a characteristic polygonal cobblestone shape, showed high levels of desmoglein 3 and cytokeratin 5 (K5) expression as assessed by real-time PCR, and were assessed to be viable by the MTT assay (data not shown).

Approximately 45% ( $45 \pm 1.0$ ;  $n = 5$ ) of the differentiated ADSCs stained positive for K10, although undifferentiated ADSCs did not (Fig. 2A). NHEKs were stained with anti-K10 as positive control (Fig. 2A). ADSCs were also immunostained for human K5 and K14. However, undifferentiated ADSCs as well as differentiated ADSCs were positive for K5 and K14, which are markers specific for the basal layer, although the degree of staining slightly increased after differentiation (data not shown).

Flow cytometry revealed that the differentiated ADSCs expressed K10 (Fig. 2B).

Real-time PCR also revealed that the differentiated ADSCs expressed higher levels of K10 than the undifferentiated ADSCs and ADSCs co-cultured with NHDFs without ATRA and BMP4 ( $p < 0.05$ ) (Fig. 2C).

### **80% of differentiated ADSCs expressed Col7**

Approximately 80% ( $80 \pm 2.0$ ;  $n = 5$ ) of differentiated ADSCs stained positive, although undifferentiated ADSCs showed no Col7 immunostaining (Fig. 3A). NHEKs were immunostained with anti-human Col7 as a positive control (Fig. 3A).

Flow cytometry revealed that the differentiated ADSCs expressed Col7 (Fig. 3B).

Real-time PCR also revealed that differentiated ADSCs expressed much higher levels of Col7 than undifferentiated ADSCs and ADSCs co-cultured with NHDFs without ATRA and BMP4 ( $p < 0.05$ ) (Fig. 3C).

Western blotting also revealed that the differentiated ADSCs expressed higher levels of Col7 than the undifferentiated ADSCs and ADSCs co-cultured with NHDFs without ATRA and BMP4 (Fig. 3D).

## **Discussion**

Recessive dystrophic epidermolysis bullosa (RDEB) is caused by mutations in the *COL7A1* gene encoding for Col7 [4]. Thus, patients with RDEB suffer from blistering and repeated wounding of the skin, oral mucosa, and gastrointestinal tract. The use of regenerative medicine to treat severe types of epidermolysis bullosa is beginning to attract attention. In particular, the use of autologous or allogeneic cultured skin grafts is reported to be beneficial for intractable ulcers [1, 3, 6]. Autologous cultured epidermal grafts can be used as permanent coverings, although these cells contain Col7 with the

mutations. Allogeneic skin substitutes, on the other hand, are not permanently adopted. In any case, both of these skin grafts are used as biological dressings. Recently, stem cell therapies for the treatment of RDEB have been developed. The advantages of using ADSCs include their abundance in donors and the ease with which they can be obtained using relatively noninvasive methods such as liposuction. Moreover, ADSCs show low immunogenicity and have powerful immunosuppressive potential [5, 7, 8]. For these reasons, stem cell therapies using allogeneic ADSCs may be applicable for the treatment of RDEB, although anti-Col7 antibodies may be relatively common among RDEB patients [9].

Characterization of keratinocytes and estimations of differentiation efficiencies into keratinocytes are difficult. This study showed the presence of the epithelial basal cell markers K5/14 in undifferentiated ADSCs, and the presence of K10, which is an early marker of epidermal differentiation expressed in all suprabasal cell layers, including the stratum corneum, in differentiated ADSCs. In addition, we showed that ADSCs express higher levels of Col7 under specific conditions. These findings support the therapeutic potential of ADSCs, not only for wound healing, but also for the correction of Col7



deficiencies. However, the method for ADSC administration is still unresolved. The immunogenicity of differentiated ADSCs should be also investigated in future studies.

### **Acknowledgements**

The authors thank Niyonsaba François, Mutsuko Hara, Yuko Kojima, Tamami Sakanishi, Hiroshi Koide, Tomomi Ikeda, and Reiko Mineki for helpful discussions and technical assistance.

**Compliance with ethical standards****Conflict of Interest**

The authors declare that they have no conflict of interest.

**Funding**

This study was supported by JSPS KAKENHI Grant Number JP16K10176.

**Ethical approval**

The study protocol was approved by the Ethics Committee of the Juntendo University Graduate School of Medicine. Data were analyzed in a blinded fashion, and procedures were carried out according to the principles of the Declaration of Helsinki.

**Informed consent**

Informed, written consent was obtained from all study participants.

## References

1. Beele H, Naeyaert JM, Monstrey S, Kint A. (1995) Ulcers in pretibial epidermolysis bullosa. Grafting with autologous meshed split-thickness skin and allogeneic cultured keratinocytes. *Arch Dermatol* 131:990-992.
2. Hasegawa T, Sakamoto A, Wada A, Fukai T, Ikeda S. (2015) Keratinocyte progenitor cells reside in human subcutaneous adipose tissue. *PLoS One* 10: e0118402
3. Hasegawa T, Suga Y, Mizoguchi M, Ikeda S, Ogawa H, Kubo K, Matsui H, Kagawa S, Kuroyanagi Y. (2004) Clinical trial of allogeneic cultured dermal substitute for the treatment of intractable skin ulcers in 3 patients with recessive dystrophic epidermolysis bullosa. *J Am Acad Dermatol* 50:803-804.
4. Hilal L, Rochat A, Duquesnoy P, Blanchet-Bardon C, Wechsler J, Martin N, Christiano AM, Barrandon Y, Uitto J, Goossens M, Hovnanian A. (1993) A homozygous insertion-deletion in the type VII collagen gene (COL7A1) in Hallopeau-Siemens dystrophic epidermolysis bullosa. *Nat Genet* 5:287-293.
5. Lombardo E, DelaRosa O, Mancheño-Corvo P, Menta R, Ramírez C, Büscher D. (2009) Toll-like receptor-mediated signaling in human adipose-derived stem cells:

implications for immunogenicity and immunosuppressive potential. *Tissue Eng Part A* 15:1579-1589.

6. McGrath JA, Schofield OM, Ishida-Yamamoto A, O'Grady A, Mayou BJ, Navsaria H, Leigh IM, Eady RA. (1993) Cultured keratinocyte allografts and wound healing in severe recessive dystrophic epidermolysis bullosa. *J Am Acad Dermatol* 29:407-419.
7. McIntosh K, Zvonic S, Garrett S, Mitchell JB, Floyd ZE, Hammill L, Kloster A, Di Halvorsen Y, Ting JP, Storms RW, Goh B, Kilroy G, Wu X, Gimble JM. (2006) The immunogenicity of human adipose-derived cells: temporal changes in vitro. *Stem Cells* 24:1246-1253.
8. Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, Taureau C, Cousin B, Abbal M, Laharraqe P, Penicaud L, Casteilla L, Blancher A. (2005) Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. *Br J Haematol* 129:118-129.
9. Woodley DT, Cogan J, Wang X, Hou Y, Haghghian C, Kudo G, Keene DR, Chen M. (2014) De novo anti-type VII collagen antibodies in patients with recessive dystrophic epidermolysis bullosa. *J Invest Dermatol* 134:1138-1140.

10. Yu G, Floyd ZE, Wu X, Hebert T, Halvorsen YD, Buehrer BM, Gimble JM. (2011) Adipogenic differentiation of adipose-derived stem cells. *Methods Mol Biol* 702: 193–200.
11. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. (2001) Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng* 7:211-228.

**Figure legends****Fig. 1.**

K14 detection in ADSCs. (A) Undifferentiated ADSCs were immunostained with anti-K14. NHEKs were also immunostained with anti-K14 as a positive control. (B) K14 expression in undifferentiated ADSCs was detected by flow cytometry. (C) K14 expression was measured by quantitative real-time PCR in undifferentiated ADSCs and cells that had differentiated into adipocytes. (D) K14 expression was measured by western blotting (relative to  $\beta$ -actin) in undifferentiated ADSCs and those that had differentiated into adipocytes.

**Fig. 2.**


K10 detection in ADSCs. (A) Undifferentiated and differentiated ADSCs were immunostained with anti-K10. NHEKs were also immunostained with anti-human K10 as positive control. (B) K10 expression in differentiated ADSCs was detected by flow cytometry. (C) K10 expression was confirmed by real-time PCR.

**Fig. 3.**


Col7 detection in ADSCs. (A) Col7 expression in undifferentiated and differentiated ADSCs was detected by immunofluorescence. NHEKs were also immunostained with anti-human Col7 as positive control. (B) Col7 expression in differentiated ADSCs was detected by flow cytometry. (C) Col7 expression was confirmed by real-time PCR. (D) Col7 expression was detected by western blotting.

K14

undifferentiated ADSCs




normal human epidermal keratinocytes (NHEKs)







K14


undifferentiated ADSCs



### K14 expression (real-time PCR)










K10

— undifferentiated ADSCs  
— differentiated ADSCs




### K10 expression (real-time PCR)





Col7

- undifferentiated ADSCs
- differentiated ADSCs





## Col7 expression (real-time PCR)

